Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 21 results for tamoxifen

  1. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk...

  2. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately...

  3. Advanced breast cancer: diagnosis and treatment (CG81)

    This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.

  4. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  5. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

  6. Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

    Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.

  7. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  8. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

  9. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    it, women could think about taking one of two other medicines, called tamoxifen and raloxifene. The key points to think about are as...

  10. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    it, women could think about taking one of two other medicines, called tamoxifen and raloxifene. The key points to think about are as...

  11. Patient decision aids

    cancer taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk taking...

  12. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  13. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)

    Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.

  14. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.